In 2024, the operating profit of ToolGen amounted to a loss of around 21.8 billion South Korean won. The company has not seen an operating profit in recent years. ToolGen is a South Korean biotech company specialized in CRISPR genome editing technology.
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield
Vice President, Hearst Magazines
Global overview
Research & development
R&D country comparison
Products
Funding/M&A/IPOs
Focus: U.S. companies
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
